Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Keratosis, Actinic 18Keratosis 3Condylomata Acuminata 3Carcinoma, Basal Cell 3Urinary Bladder Neoplasms 2Non-Muscle Invasive Bladder Neoplasms 2Glioblastoma 2Warts 1Vulvar High Grade Squamous Intraepithelial Lesion (HSIL) 1Virus Diseases 1Sialorrhea 1Sexually Transmitted Diseases 1Papillomavirus Infections 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Glioma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma in Situ 1Atypical Squamous Cells of the Cervix 1Adenocarcinoma 1

Interventions

Mitomycin 15Gemcitabine 13dodecyl maltoside 5BCG Vaccine 5erdafitinib 4apaziquone 4ALT-803 4Epirubicin 3viscum album peptide 2durvalumab 2VB4-845 2Imiquimod 2Docetaxel 25-aminolevulinic acid hexyl ester 21-phenyl-3,3-dimethyltriazene 2vocimagene amiretrorepvec 1valrubicin 1pirarubicin 1pembrolizumab 1linrodostat 1hydroxycamptothecinum 1enfortumab vedotin 1catumaxomab 1Water 1Therapeutics 1Therapeutic Uses 1Standard of Care 1Polysorbates 1Photochemotherapy 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Non-Muscle Invasive Bladder Neoplasms × Imiquimod × Clear all
NCT05375903 2026-01-14

A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

UroGen Pharma Ltd.

Phase 1 Completed
51 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT01731652 2015-02-10

Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer

Telormedix SA

Phase 2 Completed
12 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

Data powered by HemOnc (CC BY 4.0) Colophon âš¡